<p>Spyglass Pharma, Inc.（纳斯达克代码：SGP - 获取免费报告）在周五的午盘交易中，股价上涨了 5.3%。该公司的股价最高达到 27.97 美元，最后交易价格为 27.82 美元。在午盘交易中，共成交 39,616 股，较平均交易量 91,525 股下降了 57%。该股票之前的收盘价为 26.42 美元。</p>
<p>获取 <strong>Spyglass Pharma</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>几位股票分析师最近对 SGP 股票发表了看法。杰富瑞金融集团在周二的一份研究报告中开始覆盖 Spyglass Pharma 的股票。他们给予该公司 “买入” 评级，并设定 62.00 美元的目标价格。Zacks Research 在周三将 Spyglass Pharma 的股票评级上调至 “持有”。Stifel Nicolaus 在周二的一份报告中开始覆盖 Spyglass Pharma 的股票。他们对该股票设定了 “买入” 评级和 42.00 美元的目标价格。Leerink Partners 在周二的一份研究报告中将 Spyglass Pharma 的评级下调至 “市场表现”。最后，花旗集团在周二的一份研究报告中开始覆盖 Spyglass Pharma。他们给予该公司 “买入” 评级，并设定 42.00 美元的目标价格。四位研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价格为 47.00 美元。</p>
<p><strong>查看我们对 SGP 的最新分析</strong></p>
<h2>Spyglass Pharma 股价上涨 5.6%</h2>
<h2>Spyglass Pharma 的内部活动</h2>
<p>在其他 Spyglass Pharma 的新闻中，董事 Ra Capital Management, L.P.在 2 月 9 日（星期一）购买了 3,690,000 股该公司的股票。每股购买价格为 16.00 美元，总交易额为 59,040,000.00 美元。交易完成后，该董事直接持有该公司 5,966,439 股股票，价值 95,463,024 美元。这笔交易代表了他们对该股票持有量的 162.10% 的增加。该购买在向证券交易委员会提交的文件中披露，文件可在 SEC 网站上获取。</p>
<h2>Spyglass Pharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>我们是一家晚期生物制药公司，致力于通过长期有效的药物递送改变慢性眼病患者的治疗模式。我们的使命是通过开发耐用的药物递送解决方案，显著改善慢性眼病患者的生活，使患者和外科医生在长期控制疾病和保护视力方面充满信心。我们的主要产品候选者是 Bimatoprost 药物垫-IOL 系统（BIM-IOL 系统），该系统由新型专有药物垫与我们的人工晶状体（IOL）相结合，旨在在常规白内障手术中植入，以降低患有开角型青光眼（OAG）或眼压升高（OHT）患者的眼内压（IOP）。</p>
<h2>另请参见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Spyglass Pharma</li>
<li>埃隆是否在为银色冲击做准备？</li>
<li>BNZI 在 Zacks 的买入推荐中脱颖而出。盈利动能和分析师升级一致</li>
<li>您的名字尚未在我们的保护名单上</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>用这 4 个简单步骤 “防止美联储影响” 您的银行账户</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Spyglass Pharma 吗？</h2>
<p>在您考虑 Spyglass Pharma 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Spyglass Pharma 并不在名单上。</p>
<p>虽然 Spyglass Pharma 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Spyglass Pharma（纳斯达克代码：SGP）股价在午盘交易中上涨了 5.3%，达到 27.82 美元，尽管成交量较平均水平下降了 57%。分析师的评级各不相同，Jefferies 和 Stifel Nicolaus 给予 “买入” 评级，目标价分别为 62.00 美元和 42.00 美元。Zacks 将该股票评级上调至 “持有”，而 Leerink Partners 则将其评级下调至 “市场表现”。一名内部人士最近购买了 369 万股，显著增加了其持股比例。该股票的平均评级为 “适度买入”，目标价为 47.00 美元</p>

<p>Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report)'s share price traded up 5.3% during mid-day trading on Friday . The company traded as high as $27.97 and last traded at $27.82. 39,616 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 91,525 shares. The stock had previously closed at $26.42.</p>
<div class="lb-trans"><p>Spyglass Pharma, Inc.（纳斯达克代码：SGP - 获取免费报告）在周五的午盘交易中，股价上涨了 5.3%。该公司的股价最高达到 27.97 美元，最后交易价格为 27.82 美元。在午盘交易中，共成交 39,616 股，较平均交易量 91,525 股下降了 57%。该股票之前的收盘价为 26.42 美元。</p>
</div><p>Get <strong>Spyglass Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Spyglass Pharma</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several equities analysts have recently weighed in on SGP shares. Jefferies Financial Group assumed coverage on shares of Spyglass Pharma in a research note on Tuesday. They issued a &#34;buy&#34; rating and a $62.00 target price for the company. Zacks Research upgraded shares of Spyglass Pharma to a &#34;hold&#34; rating in a research note on Wednesday. Stifel Nicolaus assumed coverage on shares of Spyglass Pharma in a report on Tuesday. They set a &#34;buy&#34; rating and a $42.00 target price on the stock. Leerink Partners downgraded Spyglass Pharma to a &#34;market perform&#34; rating in a research report on Tuesday. Finally, Citigroup assumed coverage on Spyglass Pharma in a research report on Tuesday. They issued a &#34;buy&#34; rating and a $42.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and an average target price of $47.00.</p>
<div class="lb-trans"><p>几位股票分析师最近对 SGP 股票发表了看法。杰富瑞金融集团在周二的一份研究报告中开始覆盖 Spyglass Pharma 的股票。他们给予该公司 “买入” 评级，并设定 62.00 美元的目标价格。Zacks Research 在周三将 Spyglass Pharma 的股票评级上调至 “持有”。Stifel Nicolaus 在周二的一份报告中开始覆盖 Spyglass Pharma 的股票。他们对该股票设定了 “买入” 评级和 42.00 美元的目标价格。Leerink Partners 在周二的一份研究报告中将 Spyglass Pharma 的评级下调至 “市场表现”。最后，花旗集团在周二的一份研究报告中开始覆盖 Spyglass Pharma。他们给予该公司 “买入” 评级，并设定 42.00 美元的目标价格。四位研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价格为 47.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on SGP</strong></p>
<div class="lb-trans"><p><strong>查看我们对 SGP 的最新分析</strong></p>
</div><h2>Spyglass Pharma Trading Up 5.6%</h2>
<div class="lb-trans"><h2>Spyglass Pharma 股价上涨 5.6%</h2>
</div><h2>Insider Activity at Spyglass Pharma</h2>
<div class="lb-trans"><h2>Spyglass Pharma 的内部活动</h2>
</div><p>In other Spyglass Pharma news, Director Ra Capital Management, L.P. bought 3,690,000 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The shares were bought at an average price of $16.00 per share, for a total transaction of $59,040,000.00. Following the transaction, the director directly owned 5,966,439 shares in the company, valued at $95,463,024. This trade represents a 162.10% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website.</p>
<div class="lb-trans"><p>在其他 Spyglass Pharma 的新闻中，董事 Ra Capital Management, L.P.在 2 月 9 日（星期一）购买了 3,690,000 股该公司的股票。每股购买价格为 16.00 美元，总交易额为 59,040,000.00 美元。交易完成后，该董事直接持有该公司 5,966,439 股股票，价值 95,463,024 美元。这笔交易代表了他们对该股票持有量的 162.10% 的增加。该购买在向证券交易委员会提交的文件中披露，文件可在 SEC 网站上获取。</p>
</div><h2>Spyglass Pharma Company Profile</h2>
<div class="lb-trans"><h2>Spyglass Pharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).</p>
<div class="lb-trans"><p>我们是一家晚期生物制药公司，致力于通过长期有效的药物递送改变慢性眼病患者的治疗模式。我们的使命是通过开发耐用的药物递送解决方案，显著改善慢性眼病患者的生活，使患者和外科医生在长期控制疾病和保护视力方面充满信心。我们的主要产品候选者是 Bimatoprost 药物垫-IOL 系统（BIM-IOL 系统），该系统由新型专有药物垫与我们的人工晶状体（IOL）相结合，旨在在常规白内障手术中植入，以降低患有开角型青光眼（OAG）或眼压升高（OHT）患者的眼内压（IOP）。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Spyglass Pharma</li>
<li>Is Elon Preparing for a Silver Shock?</li>
<li>BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align</li>
<li>Your name isn't on our protected list yet</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Spyglass Pharma</li>
<li>埃隆是否在为银色冲击做准备？</li>
<li>BNZI 在 Zacks 的买入推荐中脱颖而出。盈利动能和分析师升级一致</li>
<li>您的名字尚未在我们的保护名单上</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>用这 4 个简单步骤 “防止美联储影响” 您的银行账户</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spyglass Pharma Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Spyglass Pharma 吗？</h2>
</div><p>Before you consider Spyglass Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Spyglass Pharma 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Spyglass Pharma 并不在名单上。</p>
</div><p>While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Spyglass Pharma 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

SpyGlass Pharma（NASDAQ:SGP）股价上涨 5.3% - 事件详情如下